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Abstract
Background: Whole blood expression profiling is frequently performed using
PAXgene (Qiagen) or Tempus (Life Technologies) tubes. Here, we compare 6 novel
generation RNA isolation protocols with respect to RNA quantity, quality and
recovery of mRNA and miRNA.
Methods: 3 PAXgene and 3 Tempus Tubes were collected from participants of the
LIFE study with (n512) and without (n535) acute myocardial infarction (AMI). RNA
was extracted with 4 manual protocols from Qiagen (PAXgene Blood miRNA Kit),
Life Technologies (MagMAX for Stabilized Blood Tubes RNA Isolation Kit), and
Norgen Biotek (Norgen Preserved Blood RNA Purification Kit I and Kit II), and 2
(semi-)automated protocols on the QIAsymphony (Qiagen) and MagMAX Express-
96 Magnetic Particle Processor (Life Technologies). RNA quantity and quality was
determined. For biological validation, RNA from 12 representative probands,
extracted with all 6 kits (n572), was reverse transcribed and mRNAs (matrix
metalloproteinase 9, arginase 1) and miRNAs (miR133a, miR1), shown to be
altered by AMI, were analyzed.
Results: RNA yields were highest using the Norgen Kit I with Tempus Tubes and
lowest using the Norgen Kit II with PAXgene. The disease status was the second
major determinant of RNA yields (LIFE-AMI 11.2 vs. LIFE 6.7 mg, p,0.001)
followed by the choice of blood collection tube. (Semi-)automation reduced overall
RNA extraction time but did not generally reduce hands-on-time. RNA yields and
quality were comparable between manual and automated extraction protocols.
mRNA expression was not affected by collection tubes and RNA extraction kits but
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Citation: Häntzsch M, Tolios A, Beutner F, Nagel
D, Thiery J, et al. (2014) Comparison of Whole
Blood RNA Preservation Tubes and Novel
Generation RNA Extraction Kits for Analysis of
mRNA and MiRNA Profiles. PLoS ONE 9(12):
e113298. doi:10.1371/journal.pone.0113298
Editor: Rolf Müller, Philipps University, Germany
Received: August 1, 2014
Accepted: October 24, 2014
Published: December 3, 2014
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by RT/qPCR reagents with exception of the Norgen Kit II, which led to mRNA
depletion. For miRNAs, expression differences related to collection tubes (miR30b),
RNA isolation (Norgen Kit II), and RT/qRT reagents (miR133a) were observed.
Conclusion: We demonstrate that novel generation RNA isolation kits significantly
differed with respect to RNA recovery and affected miRNA but not mRNA
expression profiles.
Introduction
Gene expression profiling in peripheral blood is frequently performed to identify
susceptibility genes or biomarkers for human traits or diseases. Upon collection,
RNA profiles change within minutes [1, 2]. Therefore, PAXgene (Qiagen) and
Tempus (Life Technologies) Blood RNA Tubes, which allow instant preservation
of RNA, are widely used. The suppliers of both types of tubes offer corresponding
RNA extraction kits as well as reagents for downstream applications such as
reverse transcription (RT) and quantitative real time (qRT)-PCR assays for
quantification of target transcripts. Whereas older extraction kits were optimized
for isolation of mRNA (PAXgene blood RNA Kit, Tempus Spin RNA Isolation
Kit) [3, 4], more recent assays were designed to also efficiently extract miRNAs
(PAXgene blood miRNA Kit, MagMAX for Stabilized Blood Tubes RNA
Isolation).
In the meantime, additional suppliers have launched extraction kits for
PAXgene and Tempus Blood RNA Tubes, which are also optimized for parallel
mRNA and small RNA extraction (Norgen). Extraction methods vary depending
on the manufacturer and are either based on silica-membranes (e.g. Qiagen,
Norgen) or magnetic beads (e.g. Life Technologies) [5]. Whereas previous work
has investigated quantity and quality of RNA isolated by kits using the same
extraction principle from different preservation tubes [3, 6, 7], comparison of
more recently available extraction kits, which are based on different extraction
principles and allowing efficient parallel mRNA and miRNA extraction has not
been performed, yet.
Besides miRNA/mRNA quality and quantity, the duration of extraction is
critical and automated sample processing is warranted especially in larger studies.
Qiagen and Life Technologies provide companion instruments to facilitate RNA
extraction, allowing parallel processing of up to 96 samples. To date, however, a
comparison of the duration of sample processing as well as required hands-on
times using different manual and (semi-)automated extraction methods has not
been performed.
After extraction, RNA expression may be analyzed by genome-wide approaches,
either using array [8–10] or sequencing techniques [11–14]. Both are still cost-
intensive and thus, quantitative RT-PCR (qRT-PCR) [15, 16], is frequently used
for determination of target gene expression. qRT-PCR requires prior reverse
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transcription of RNA into cDNA. Both, mRNA and miRNA, can be reverse
transcribed in parallel using Qiagen reagents with non-specific Oligo(dT) primers
after polyadenylation of all RNAs, whereas mRNA and miRNA are independently
reverse transcribed with Life Technologies reagents using non-specific primers for
mRNA or stem loop-specific primers for each miRNA. To the best of our
knowledge, studies comparing the effects of different blood collection tubes in
combination with different downstream RT and qRT-PCR reagents are lacking.
Thus, the aim of the current study was (1) to compare different extraction
systems (filter-based vs. magnetic beads; manual vs. automated) for PAXgene and
Tempus Blood RNA Tubes with regard to the quantity and quality of RNA, (2) to
test different extraction protocols for the duration of extraction, hands-on time
and processing time per sample, and (3) to evaluate mRNA and miRNA
expression depending on the collection tube, RNA extraction method, RT and
qRT-PCR reagents that were used. Studies were performed in probands of the
LIFE study, which is an cohort study of the population of Leipzig, and in the LIFE
Heart substudy, which recruits patients with myocardial infarction (AMI)
[17, 18]. For biological validation, expression of representative genes, which were
previously shown to be altered by AMI, such as matrix metalloproteinase 9
(MMP9) and arginase 1 (ARG1) [19–21] and miRNAs miR133a and miR1
[15, 22–25], were investigated.
Materials and Methods
Ethics statement, blood collection and study design
Studies were approved by the local ethics committee of the University of Leipzig
(Reg. No 263-2009-14122009 and Reg. No 276-2005, respectively). Research
participants gave informed written consent. Whole blood samples were collected
from 35 probands of the LIFE study and 12 probands with acute myocardial
infarction (AMI) from the LIFE Heart study [17] (Figure 1). Three PAXgene
Blood RNA Tubes (Qiagen) and three Tempus Blood RNA Tubes (Life
Technologies) were collected per proband. After blood collection, tubes were kept
for 2 h at RT followed by incubation at -20 C̊ for 24 h. Thereafter, tubes were
transferred to -80 C̊ for at least 7 days prior to processing.
RNA isolation, quantification and quality control
6 RNA extraction protocols using 4 different RNA isolation kits were compared
(Table 1). Four kits were used for manual RNA extraction: (1) PAXgene Blood
miRNA Kit (Qiagen), (2) MagMAX for Stabilized Blood Tubes RNA Isolation Kit
(Life Technologies), (3) Norgen Preserved Blood RNA Purification Kit I (Norgen
I Kit), and (4) Norgen Preserved Blood RNA Purification Kit II (Norgen II Kit)
from Norgen Biotek. Two kits were utilized for (semi-)automated RNA
extraction: (5) QIAsymphony PAXgene Blood RNA Kit for fully automated RNA
isolation on the QIAsymphony (Qiagen) and (6) MagMAX for Stabilized Blood
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Figure 1. Study design. For comparison of extraction efficiency and RNA quality of whole blood stabilization tubes (PAXgene Blood RNA Tubes, Qiagen;
Tempus Blood RNA Tubes, Life Technologies), blood was drawn from 47 probands of the LIFE and LIFE-AMI cohorts and RNA was isolated with 4 manual
(white) and 2 (semi-)automated (light green) extraction kits. RNA quantity and quality was determined in 262 samples (20 extractions were lost due to
handling errors). Samples from 12 probands were selected for RT and qRT-PCRs. Both steps were carried out with reagents from Qiagen or Life
Technologies, respectively. Quantification of miRNA and mRNA expression was done using the ViiA7 Real-Time PCR System (Life Technologies). In Figure
S1, Table S2 and Table S3, detailed information regarding the reaction setup for RT and qRT-PCR experiments is given. rct5reaction.
doi:10.1371/journal.pone.0113298.g001
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Tubes RNA Isolation Kit for semi-automated isolation on the MagMAX Express-
96 Magnetic Particle Processor (Life Technologies). The automated RNA
extraction on the QIAsymphony was performed at the QIAGEN GmbH R&D
Department in Hilden, Germany; all other extractions were done at the Institute
of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics at the
University of Leipzig, Germany. For each manual extraction, preservation tubes
were thawed in batches of 24 PAXgene or 16 Tempus Blood RNA Tubes and
processing was done according to manufacturers’ instructions including DNAse
digestion. For the Norgen I Kit, DNAse treatment was performed with Norgen’s
RNase-Free DNase I Kit, since it was not supplied with the extraction kit
Table 1. Summary of technical characteristics of applied RNA extraction methods from PAXgene and Tempus Blood RNA Tubes.
Blood stabilization PAXgene Blood RNA Tubes Tempus Blood RNA Tubes
Storage –80˚C –80˚C –80˚C –80˚C –80˚C –80˚C




















Principle isolation magnetic beads spin columns spin columns magnetic beads magnetic beads spin columns
Thawing 2 h RT 2 h RT 2 h RT 30 min on ice 30 min on ice 30 min on ice
Processing time/
batcha
145’/24 samples 205’/24 samples 152’/24 samples 139’/16 samples 162’/16 samples 152’/16 samples
Av. total time/sampleb 69 300 89 300 69 300 89 300 109 89 300
Centrifugation and
vortexing timea
159 469 439 519 559 799
Incubation timea 59 309 179 29 259 179
Hands-on timea 209 129’ 929 699 829 569
Processing time on
instrumenta
114’ – – 309 – –
Format on instrument 24 batches (up to
96)
– – up to 96 samples – –
DNAse digestion
implemented in Kit
yes yes yes yes yes noc
Elution volume 200 ml 40 ml 50 ml 80 ml 80 ml 50 ml
Required material/not
supplied in Kit (addi-







50 ml conical tubes;
RNAse-free mico-
centrifuge tubes
50 ml conical tubes;
RNAse-free mico-
centrifuge tubes





















fuge for 50 ml con-
ical tubes (50006g;
4 C̊), orbital shaker
magnetic stand,
swing bucket centri-









aThe time for centrifugation/vortexing, incubation steps and hands-on time was determined.
bDuring centrifugation, time was used for preparation of next steps including labeling. Thus, total duration might be different from sum of single steps.
Av.5Average.
cDNase digestion was performed with RNase-Free DNase I Kit from Norgen Biotek.
doi:10.1371/journal.pone.0113298.t001
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(Table 1). Before starting the extraction procedure, each blood tube was weighed
for subsequent correlation with RNA yield (n5282; Table S1). Purified RNA
samples (n5262) were quantified using the NanoDrop ND-1000 spectro-
photometer (Fisher Scientific) and stored at 280 C̊. 20 extractions were lost due
to handling errors. From two representative probands, RNA samples from all
extractions (n56) were selected for quality testing using Agilent small RNA Kit
run on the Bioanalyzer 2100 (Agilent Technologies) according to the
manufacturer’s protocol.
Reverse transcription (RT)
72 RNA samples, which were isolated with 6 RNA extraction protocols from 12
representative probands (6 LIFE and 6 LIFE-AMI probands), were selected for
reverse transcription (RT) with Qiagen and Life Technologies reagents,
respectively (Figure S1, Table S1, Table S2, Table S3). RT of mRNA and miRNA
was performed in a single reaction using the miScript Reverse Transcription Kit
from Qiagen (n572) with the miScript RT buffer supplied with the kit. Distinct
assays from Life Technologies were necessary for RT of mRNA (Superscript VILO
cDNA synthesis Kit; n572) and each miRNA using specific stem-loop-primers
(TaqMan MicroRNA RT Kit, catalog number 4366596; n572 per miRNA). RT
was performed with 450 ng total RNA using the Qiagen miScript Reverse
Transcription Kit (for mRNA and miRNA) and the Life Technologies Superscript
VILO cDNA synthesis Kit (for mRNA). The amount of RNA was defined based on
the maximal RNA input volume of 14 ml for the Superscript VILO cDNA
synthesis Kit from Life Technologies (Table S2, Table S3) and the lowest RNA
concentration of 34.89 ng/ml (sample LIFE25, isolated with QIAsymphony, Table
S1). 10 ng RNA was used for the TaqMan MicroRNA RT Kit for each investigated
miRNA (Figure S1). All RT reactions were performed according to the
manufacturers’ instructions using an ABI GenAmp PCR System 9700 (Applied
Biosystems, Table S2, Table S3). cDNA samples were stored at 220 C̊ until
further use.
Quantitative real time PCR (qRT-PCR)
For mRNA analyses, samples were diluted with RNase free water to a final amount
of 10 ng template cDNA/sample in a volume of 2.5 ml. For miRNA quantification,
1 ng cDNA/sample/2.5 ml input were used (Table S2, Table S3). qRT-PCR
quantification of mRNA and miRNA expression was performed using assays and
accompanying reagents from either Qiagen or Life Technologies. Qiagen reagents:
mRNA analyses were performed using Quantitect Primer Assays for beta actin
(ACTB; QT01680476), matrix metalloproteinase 9 (MMP9; QT00040040) and
arginase 1 (ARG1; QT00068446). miRNA quantification was performed with
miScript Primer Assays for miR1 (MS00008358), miR16 (MS00031493), miR30b
(MS00003276) and miR133a (MS00031423). Assays were run with the miScript
SYBR Green PCR Kit for quantitative PCR (for further information see Figure S1
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and Table S2). Life Technologies reagents: TaqMan Gene Expression Assays for
ACTB (HS 99999903) MMP9 (HS 00234579) and ARG1 (HS 00968979) and
TaqMan MicroRNA Assays for miR1 (ID 002222), miR16 (ID 000291), miR30b
(ID 000602) and miR133a (ID 002246) were used in combination with the
TaqMan Fast Advanced Mastermix. Reaction setups and manufacturers’
instructions are summarized in Figure S1, Table S2, Table S3. Measurements were
performed in quadruplicates (384-well plates) in a final volume of 12.5 ml on the
ViiA7 Real-Time PCR System (Life Technologies) according to the manufac-
turers’ instructions.
Statistical analysis
Statistical analysis was done using SAS (Version 9.3, SAS Institute, Inc., Cary, NC,
USA), GraphPad PRISM (Version 6.02, GraphPad Software, Inc., La Jolla, CA,
USA), and Excel (Version 2010, Microsoft Corporation, Redmond, WA, USA).
Normality of distribution was tested using the Kolmogorov-Smirnov test. For the
calculation of RNA extraction efficiency, outliers deviating more than 2xSD from
arithmetic mean were excluded from analysis. Comparison of two groups was
done using Wilcoxon-Mann-Whitney test for non-normally distributed data,
Welch’s t-test or Student’s t-test for normally distributed data with unequal or
equal variances, respectively. Bonferroni correction for multiple testing was
applied. The DCt and DDCt method was calculated according to [26] using the
mean Ct of LIFE probands as reference.
Results
Comparison of RNA isolation from PAXgene and Tempus Blood
RNA Tubes with manual and (semi-) automated extraction kits
Two whole blood stabilizing systems, PAXgene blood RNA system (Qiagen) and
Tempus RNA system (Life Technologies), were evaluated for total RNA yield,
duration of RNA preparation and mRNA and miRNA preservation. To this end,
three PAXgene and three Tempus Blood RNA Tubes were collected from each
proband of the LIFE study with (n512) and without AMI (n535) [17] and RNA
was extracted with either manual or (semi-)automated kits of the respective
supplier and with kits from an alternative company (Norgen Biotek). The study
design is shown in Figure 1. Table 1 provides information about the time for
sample preparation, additional materials not supplied with the kits as well as
required laboratory equipment.
A major difference between both types of stabilization tubes was the time
recommended for thawing. According to the manufacturer’s instructions,
PAXgene Blood RNA Tubes should be thawed for 2 h at room temperature
whereas Tempus Blood RNA Tubes may be processed after 30 min thawing on
ice. Upon thawing, 24 or 16 samples for PAXgene or Tempus Blood RNA Tubes,
respectively, were processed in batches. The differences in numbers were due to
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the capacity of the available centrifuge (Heraeus Multifuge 3SR), which was
limited to 16 conical tubes with a volume of 50 ml required for RNA isolation
from Tempus Blood RNA Tubes with all investigated kits (Table 1).
Manual sample preparation of 24 PAXgene Blood RNA Tubes was faster using
the Norgen Preserved Blood RNA Purification Kit II (152 min total with 92 min
of hands-on time, compared to preparation with the PAXgene Blood miRNA Kit
(205 min total with 129 min of hands-on time). Manual sample preparation for
16 Tempus Blood RNA Tubes was faster with the Norgen Preserved Blood RNA
Purification Kit I (152 min total with 56 min of hands-on time), compared to the
MagMAX Stabilized Blood Tubes RNA Isolation Kit (162 min total with 82 min
of hands-on time).
Using the semi-automated MagMAX Express-96 Magnetic Particle Processor,
RNA from 16 Tempus Blood RNA Tubes was isolated within 139 min, requiring
69 min of hands-on time. Using the fully-automated QIAsymphony, RNA from 24
PAXgene Blood RNA Tubes was isolated in 145 min requiring 20 min of hands-on
time. Differences in hands-on times may largely be explained by the fact that the
QIAsymphony is a fully automated instrument, in which thawed PAXgene Blood
RNA Tubes can directly be loaded, whereas the MagMAX Express-96 Magnetic
Particle Processor mainly supports washing and elution steps. To achieve the most
economic use of reagents, it is recommended to work within batches of 24 samples on
the QIAsymphony allowing parallel processing of up to 96 samples. In contrast, any
number of samples (1 296) can be processed with the MagMAX Express-96 Magnetic
Particle Processor without loss of reagents.
The average yields of all investigated RNA extraction methods are summarized
in Figure 2, a full list of RNA yields, OD 260/280 and OD 260/230 ratios per
sample is given in Table S1. Extraction of PAXgene Blood RNA Tubes with the
Norgen Preserved Blood RNA Purification Kit II yielded significantly reduced
RNA yields compared to all other PAXgene extraction methods for LIFE (P,10–9)
and LIFE-AMI probands (P,10–5), respectively (Figure 2A,B). In contrast,
extraction of Tempus Blood RNA Tubes with kits from Life Technologies and
Norgen resulted in similar RNA yields (LIFE probands 8.5–9.3 mg; LIFE-AMI
probands 12.7–15.2 mg).
In general, both the relative and total RNA yield from LIFE probands were
approximately 30% higher for Tempus Blood RNA Tubes compared to PAXgene
Blood RNA Tubes (Figure 2A) when using the manufacturers’ kits for RNA isolation.
Relative and total RNA yields in LIFE-AMI probands were significantly higher than in
LIFE probands and independent of the blood collection tube when using the
manufacturer’s RNA extraction kits (Figure 2A,B). (Semi-)automated processing of
samples revealed comparable RNA amounts as manual processing of the kits. RNA
amounts recovered with all used RNA extraction kits were .500 ng per sample and
thus sufficient for RNA sequencing using next-generation sequencing technology.
The quality of obtained RNA was investigated in representative samples using
the Bioanalyzer 2100. Protein and organic compound contamination was
calculated using the absorbance ratios at 230, 260 and 280 nm wavelength. On
average, the 260/280 ratio was 2.04 in LIFE probands and 2.03 in LIFE-AMI
Evaluation of Novel Generation mRNA/MiRNA Whole Blood Isolation Kits
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probands, the 260/230 ratio was 1.01 in LIFE probands and 1.26 in LIFE-AMI
probands. The electropherograms and RIN values for each extraction are
illustrated in Figure 2C and revealed comparable results for all extraction methods
(RIN values 5.9–8.6), although both Norgen kits were at the lower end of the scale
(RIN 5.9–6.0).
Biological validation of RT assays and absolute qRT-PCR
quantification
For a more precise evaluation of obtained RNA, samples from 6 LIFE (mean RNA
yield 7.4 mg) and 6 LIFE-AMI probands (mean RNA yield 10.4 mg) from all 6
extraction methods were used for reverse transcription and subsequent qRT-PCR
Figure 2. Quantity and quality of RNA preserved with PAXgene and Tempus Blood RNATubes. RNA quantity and quality were determined by OD and
RNA integrity measurements. (A) RNA yield normalized to input whole blood volume (mg/g) and (B) absolute RNA recovery (mg). Significantly more RNA was
recovered in samples from LIFE-AMI probands compared to LIFE probands (11.2 mg and 6.7 mg, respectively). In LIFE-AMI probands, the choice of
collection tube did not affect RNA yields. In LIFE probands, higher RNA yields were recovered when using Tempus Blood RNATubes compared to PAXgene
Blood RNATubes (8.3 mg and 6.5 mg, respectively). Outliers and missing values were omitted according to Table S1. Data are given as mean and SEM. (C)
RNA samples extracted with six methods from representative LIFE and LIFE-AMI probands were analyzed on an Agilent Bioanalyzer. Please note the
different scales in Figure 2C. RIN5RNA integrity number.
doi:10.1371/journal.pone.0113298.g002
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(n572). All reactions were carried out with reagents from Qiagen or Life
Technologies, respectively, and the same amount of RNA was used in all
experiments. Schematics about all specifications and working steps are given in
Figure S1, Table S2 and Table S3. Processing time, e.g. hands-on time and
incubation steps, were comparable for RTs with Qiagen and Life Technologies
reagents (Table S2). However, Qiagen reagents allowed simultaneous RT of both,
mRNA and miRNA in only one reaction, whereas Life Technologies assays
required 5 RT reactions (one for mRNA and 4 for miRNAs).
For biological validation, we quantified MMP9 and ARG1 expression, since
both genes have been shown to be induced in AMI [19, 27]. Beta actin (ACTB)
was selected as house-keeping gene. For miRNAs miR133a and miR1, an increased
expression has been shown in AMI [15, 22, 23]. miR16 and miR30b were selected
as house-keeping miRNA genes, since they are highly expressed in whole blood
and expression was not altered in patients with AMI [15, 16, 28].
In general, RNA extraction from PAXgene Blood RNA Tubes using the Norgen
II Kit resulted in higher Ct-values for all quantified mRNA transcripts (Figure 3A)
but lower Ct-values for all but one of the miRNA transcripts (Figure 3B)
irrespective of the RT or qRT-PCR reagents that were used. This suggested an
enrichment of miRNAs whereas mRNAs were less efficiently recovered by this kit.
For mRNA, we observed no major effects using different collection tubes or
RNA isolation kits, whereas the use of RT and qRT-PCR reagents had a significant
effect on mRNA expression profiles: Life Technologies reagents resulted in higher
Ct-values, an effect more pronounced in higher expressed mRNAs (Figure 3A),
which might be of relevance when using the DCt- and DDCt-method for data
normalization.
The miRNA expression data were less homogeneous. miRNA quantification
was in part affected by the choice of collection tubes (e.g. mi30b, Figure 3B) and
RT and qRT-PCR reagents (miR133a, Figure 3B) as well as the extraction kit
(Norgen II Kit showed lower Ct-values in almost all analyzed samples). Notably,
mRNA and miRNA expression was comparably high so that these effects could
not be explained by lower abundance of investigated miRNAs (Figure 3A,B).
We next assessed assay robustness of mRNA/miRNA quantification by
calculating the coefficient of variation (CV) of the Ct-values (Figure 3C,D). For all
mRNA transcripts, the CVs were generally below 0.10. The exceptions were
PAXgene Blood RNA samples isolated with the Norgen II Kit in combination with
Qiagen reagents. Here, the CVs were 0.14 for ACTB, 0.11 for MMP9, and 0.08 for
ARG1, respectively (Figure 3C). For miRNA quantification, all CVs were below
0.10 with the exception of the very low expressed miR1 when samples were
reverse transcribed with Qiagen reagents (Figure 3D).
Relative differences in mRNA and miRNA expression in LIFE and
LIFE-AMI probands
DCt analysis of MMP9 and ARG1 revealed a trend towards increased expression in
LIFE-AMI compared to LIFE probands irrespective of the collection tube, RT or
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qRT-PCR reagents. Expression of house-keeping gene ACTB was not significantly
altered between the two groups (Figure 4A). Consistent with this, DDCt-analysis
of MMP9 and ARG1 expression relative to ACTB showed a trend towards up-
regulation of both genes in LIFE-AMI compared to LIFE probands (Figure S2),
which is in agreement with published literature [19, 20, 29].
With respect to miRNA quantification, results were less consistent (Figure 4B).
For miR16 and miR30b, which were initially chosen as house-keeping miRNAs, in
part inverse effects were observed depending on the RNA collection tube, RT and
qRT-PCR reagents (Figure 4B). Results for miR133a and miR1 were slightly more
robust and showed a general trend towards increased expression in LIFE-AMI
compared to LIFE probands (Figure 4B). DDCt analysis of miR133a and miR1
relative to miR16 and miR30b revealed inconsistent results (Figure S2).
Figure 3. Analyses of absolute Ct-values and coefficients of variation of investigated mRNAs and miRNAs. RNA from 12 probands, extracted with
6 RNA isolation kits from two collection tubes (PAXgene [P] and Tempus Blood RNATubes [T]) (n572) was reverse transcribed and analyzed by qRT-PCRs
with reagents from Qiagen (Q) and Life Technologies (LT). Results of qRT-PCRs showing mean Ct-values (error bars indicate SEM) for (A) mRNA and (B)
miRNA transcripts. (C,D) corresponding mean coefficients of variation (CV).
doi:10.1371/journal.pone.0113298.g003
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Discussion
In the current study, we demonstrate significant differences in RNA quantity and
quality after whole blood stabilization with PAXgene Blood RNA Tubes (Qiagen)
and Tempus Blood RNA Tubes (Life Technologies) and RNA extraction with
manual and (semi-)automated novel generation RNA isolation kits. Furthermore,
we show that mRNA expression profiling was unaffected whereas miRNA
expression levels were altered by the choice of collection tube, RNA extraction kits
and RT/qRT-PCR reagents.
Previous studies investigated mRNA expression in PAXgene and Tempus Tubes
using older generation RNA extraction kits [6, 30, 31], not specifically designed for
Figure 4. Biological validation of investigated mRNA and miRNA transcripts in LIFE-AMI and LIFE probands. DCt analysis of (A) beta actin (ACTB),
matrix metalloproteinase 9 (MMP9) and arginase 1 (ARG1) expression and (B) miR16, miR30b, miR133a and miR1 expression in in LIFE-AMI probands
compared to LIFE probands depending on the RNA extraction kit (n56) and RT/qRT-PCR reagents from Qiagen (non-shaded bars) and Life Technologies
(shaded bars), respectively. Data are given as mean and SEM.
doi:10.1371/journal.pone.0113298.g004
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extraction of miRNA. Here, we focused on novel generation kits, which allow
parallel isolation of mRNA and miRNA. In addition to extraction kits, which were
designed by the suppliers for use with the respective collection tubes (Qiagen, Life
Technologies), we also evaluated RNA isolation kits from an alternate supplier
(Norgen Biotek).
With respect to RNA yields, the Norgen Kit I in combination with Tempus
Tubes revealed highest RNA yields, whereas the Norgen Kit II with PAXgene
Tubes revealed the lowest RNA yields (60 270% less), compared to all other
isolation kits (Figure 2A,B). The disease status was the second major determinant
of RNA yields followed by the choice of blood collection tube. Notably, RNA
yields were comparable between manual and automated extraction protocols.
For biological validation, we used samples from apparently healthy individuals
from a population-based cohort (LIFE) and a cohort of patients with acute
myocardial infarction (LIFE-AMI) [17], where we found approximately 55%
higher RNA yields compared to LIFE probands (Figure 2). This finding is in line
with the observation that AMI was associated with an increased number of
peripheral leucocytes [32], which are as a major source of whole blood RNA. Since
leucocyte counts were not available, this correlation could, however, not be
investigated in the current study. In addition, the choice of collection tubes had a
significant impact on RNA yields. With Tempus Tubes, approximately 30%
higher RNA yields were recovered compared to samples that were collected with
PAXgene Tubes (Figure 2). Those results confirm findings from other groups
[6, 30, 31], which found a 80% to 160% greater RNA yield using Tempus Blood
RNA Tubes, respectively.
With respect to RNA quality, we found overall average RNA integrity numbers
(RIN) of 5.9–8.6, average OD ratios 260/280.2.0, and 260/230.1.0 (Figure 2,
Table S1), which was consistent with work from Duale et al [6]. Results were
independent of the isolation principle of the kits (silica membranes-Qiagen vs.
magnetic beads- Life Technologies). Notably, both kits from Norgen revealed
RNA integrity numbers (RIN) of 5.9–6.0, which were at the lower end of the scale
in comparison with the other investigated kits. These results highlight that the
combination of collection tubes and isolation kits from Norgen might be less
suitable in case of RNA quality-sensitive downstream analyses. For applications
where RNA quality is not critical, these RNA isolation kits may be superior in
RNA recovery and may reduce costs for RNA isolation.
We also evaluated the duration of sample preparation and compared manual
and (semi-) automated extraction protocols. In general, automated extraction
protocols were slightly faster than manual protocols. The fastest manual RNA
extractions were those from Norgen Biotek for both, PAXgene and Tempus Tubes
(152 min, each), which also required least hands-on-time compared to manual
kits from Qiagen and Life Technologies (Table 1). The fastest automated
extraction was the one using the MagMAX Express-96 Magnetic Particle
Processor (Life Technologies, 139 min). As opposed to manual processing of the
kits, automation with the QIAsymphony (Qiagen) or the MagMAX Express-96
Magnetic Particle Processor (Life Technologies) reduced the total extraction time
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by 30% and 14%, respectively, and led to a reduction of hands-on-time by 84%
and 16%, respectively (Table 1). Notably, semi-automated processing of 16
Tempus Tubes required 23% longer hands-one-time compared to the fastest
manual protocol for the same samples (69 min opposed to 56 min for the Norgen
Preserved Blood RNA Kit I, Table 1). Thus, results of the current study highlight
that counterintuitively, (semi-)automation did not lead to a reduction of hands-
on-time in general.
We further evaluated potential impacts of the novel generation RNA isolation
kits on mRNA and miRNA profiles. With exception of the Norgen Preserved
Blood RNA Purification Kit II, we demonstrate that mRNA expression profiles of
selected candidate genes were not affected by the type of collection tube and by
different RNA isolation kits (Figure 3). MMP9 and ARG1 mRNA expression was
investigated because these genes were shown to be induced in patients with AMI
[19, 20, 29]. In the current study, we confirmed upregulation of both genes in
LIFE-AMI (Figure 4), providing a biological validation of the kits used in this
study.
In contrast, miRNA expression profiles were affected by the type of collection
tubes (e.g. miR30b), RNA extraction kit (Norgen Preserved Blood RNA
Purification Kit I, e.g. miR16, miR30b, miR133a, miR1), and RT/qRT-PCR
reagents (e.g. miR133a) (Figure 3). miR1 and miR133a have been identified as
markers of AMI [15, 23], however, the association of miRNA expression with
disease status revealed inconsistent results in the current study (Figure 4). This
might in part be explained by the small study size (LIFE-AMI (n56) vs. LIFE
(n56)) but also by the aforementioned confounding effects of collection tubes
and processing steps on miRNA quantification. Results from our study thus
demonstrate that in principal, recovery of both, mRNA and miRNA, is achieved
with novel generation RNA isolation kits but that standardization of sample
processing including RT and qRT-PCR is essential, in particular when miRNA
expression is investigated.
Taken together, our study shows significant differences in RNA recovery and
quality using different RNA collection tubes in combination with manual and
(semi-)automated novel generation RNA extraction kits. It demonstrates that
mRNA expression was rather stable but miRNA levels were affected by the
collection tubes and processing steps. In case of multi-center studies or replication
studies, where samples might have been collected and processed according to
different protocols, special attention should be paid to adjust for these potentially
confounding factors.
Supporting Information
Figure S1. Extended information on reverse transcription (RT) and qRT-PCR
study design. RNA samples from 12 probands (6 LIFE probands, 6 LIFE-AMI
probands) were selected for downstream application using reagents from Qiagen
and Life Technologies. Analysis of mRNA and miRNA was carried out using the
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ViiA 7 (Life Technologies). The detailed experimental setup for RT and qRT-PCR
is summarized in Table S2 and Table S3.
doi:10.1371/journal.pone.0113298.s001 (TIF)
Figure S2. RT and qRT-PCR results of selected mRNAs and miRNAs in
dependency of RNA extraction kits. Expression of (A) matrix metalloproteinase
9 (MMP9) and arginase 1 (ARG1) and (B) miR133a and miR1 in LIFE-AMI
relative to LIFE probands. mRNA and miRNA was normalized to beta-actin
(ACTB) or either to miR16 or miR30b, respectively. Fold changes and SEM were
calculated according to [26]. Whereas differences in mRNA levels between kits
were minor, major differences were found for miRNA levels. Absolute Ct-values
are shown in Figure 3, non-normalized mean fold changes and SEM are illustrated
in Figure 4.
doi:10.1371/journal.pone.0113298.s002 (TIF)
Table S1. Characteristics of the extracted RNA. Total amount, concentration
and OD values of RNA extracted from PAXgene Tubes (A) and Tempus Tubes
(B) and blood weight for LIFE probands (LIFE1– LIFE35) and LIFE-AMI
probands (LIFE-AMI1– LIFE-AMI12) were measured. Before starting the RNA
extraction procedure, the RNA Blood tubes were weighted. Empty PAXgene
Tubes and Tempus Tubes were used as tare weight. After each RNA extraction
(using the six methods described in the manuscript), RNA yield was measured
using Nanodrop. Samples were excluded (–) where total RNA amount was too
low likely due to inaccurate handling. Furthermore, cells in green indicate RNA
yield out of the 95% distribution. These values were omitted for the analyses in
Figure 2. Samples marked in yellow were used for downstream analyses including
reverse transcription and qRT-PCR (see Figure S1).
doi:10.1371/journal.pone.0113298.s003 (XLSX)
Table S2. Specifications of reverse transcription (RT) and qRT-PCR using
reagents from Qiagen and Life Technologies. Detailed information on the used
volumes and dilutions is given in Figure S1 and Table S3. rct5reaction.
doi:10.1371/journal.pone.0113298.s004 (XLSX)
Table S3. Setup for RT and Real-time PCR. Overview including all reaction setup
for the processing of Reverse Transcription (RT) and quantitative real-time PCR
using kits from Qiagen and Life Technologies. rct5reaction.
doi:10.1371/journal.pone.0113298.s005 (XLSX)
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